Liposomes as vehicles for targeted therapy of cancer. Part 2: Clinical development

被引：35
作者：
Harrington, KJ
Lewanski, CR
Stewart, JSW
机构：
[1] Mayo Clin, Program Mol Med, Rochester, MN 55902 USA
[2] Hammersmith Hosp, Imperial Canc Res Fund, Imperial Coll Sci Technol & Med, Oncol Unit, London, England
[3] Charing Cross Hosp, Dept Radiotherapy, London, England
来源：
CLINICAL ONCOLOGY | 2000年 / 12卷 / 01期
关键词：
D O I：
10.1053/clon.2000.9105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：16 / 24
页数：9
相关论文
共 81 条
[1]  
AHMAD I, 1993, CANCER RES, V53, P1484
[2]  
BATIST G, 1999, P AN M AM SOC CLIN, V18, pA127
[3]  
BATIST G, 1998, P AN M AM SOC CLIN, V17, pA115
[4]   The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin [J].
Berry, G ;
Billingham, M ;
Alderman, E ;
Richardson, P ;
Torti, F ;
Lum, B ;
Patek, A ;
Martin, FJ .
ANNALS OF ONCOLOGY, 1998, 9 (07) :711-716
[5]  
BOGNER JR, 1994, J ACQ IMMUN DEF SYND, V7, P463
[6]  
CHACHOUA A, 1987, CANCER TREAT REP, V71, P775
[7]  
CHEUNG TW, 1998, P ASCO, V17, pA42
[8]  
Clark PR, 1999, CURR OPIN MOL THER, V1, P158
[9]  
COLBERN GT, 1998, P AN M AM SOC CLIN, V17, pA238
[10]  
CORTES J, 1998, P ASCO, V17, pA5
123456789